Article

Genomic Signature of MTOR Could Be an Immunogenicity Marker in Human Colorectal Cancer

2022-02-21

Abstract excerpt

<title>Abstract</title> <p>Background The mTOR signaling pathway plays an important role in cancer. As a master regulator, the status of <italic>MTOR</italic> affects pathway activity and the efficacy of mTOR inhibitor therapy. However, little research has been performed to explore <italic>MTOR</italic> in colorectal cancer (CRC). Methods In this study, gene expression and clinical data were analyzed using The...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 02b52427-1252-5b92-9d97-f32f80c049a0
DOI: 10.21203/rs.3.rs-1249776/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Genomic Signature of MTOR Could Be an Immunogenicity Marker in Human Colorectal CancerDOI 10.21203/rs.3.rs-1249776/v1Read

TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal CancerSemantic proximity Read

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.Semantic proximity Read

Frameshift mutations in mammalian target of rapamycin pathway genes and their regional heterogeneity in sporadic colorectal cancers.Semantic proximity Read

Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.Semantic proximity Read

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumorsSemantic proximity Read

Analysis of autophagy-related gene signature associated with clinical prognosis and immune microenvironment in colorectal cancerSemantic proximity Read

CRC genome-driven metabolic reprogramming and immune microenvironment remodelingSemantic proximity Read

The clinical implications of immunogenomics in colorectal cancer: A path for precision medicineSemantic proximity Read